Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Solymbic

- PMLiVE

Humira gets OK for childhood psoriasis in Europe

First biologic drug to be approved in the region for children as young as four

- PMLiVE

Amgen gets quick US review for Kyprolis

To be considered as a second-line therapy for multiple myeloma

- PMLiVE

AbbVie: New firm, new thinking

UK general manager Matt Regan talks to PME about creating an evolved culture from Abbott

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

- PMLiVE

Icelandic genome study yields new disease genes

Nature Medicine study focuses on the probability of developing Alzheimer’s

- PMLiVE

The end of hepatitis C?

Next-gen hep C therapies may see the disease's global elimination - but treament access must be stepped up dramatically

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

- PMLiVE

AbbVie to acquire cancer biopharma Pharmacyclics for $21bn

Comes six months after the US firm pulled out of a $54bn deal with Shire

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

EU flag

Jinarc backed for European approval in rare kidney disease

Positive opinion for Otsuka comes just before rare disease awareness day

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links